MA53861B1 - Modulateurs de promédicaments de la voie de réponse intégrée au stress - Google Patents
Modulateurs de promédicaments de la voie de réponse intégrée au stressInfo
- Publication number
- MA53861B1 MA53861B1 MA53861A MA53861A MA53861B1 MA 53861 B1 MA53861 B1 MA 53861B1 MA 53861 A MA53861 A MA 53861A MA 53861 A MA53861 A MA 53861A MA 53861 B1 MA53861 B1 MA 53861B1
- Authority
- MA
- Morocco
- Prior art keywords
- prodrug
- modulators
- stress response
- integrated stress
- response pathway
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 230000009221 stress response pathway Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003938 response to stress Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des composés, des compositions et des procédés utiles pour moduler la réponse intégrée au stress (ris) et pour traiter des maladies, troubles et états associés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862744293P | 2018-10-11 | 2018-10-11 | |
PCT/US2019/055850 WO2020077217A1 (fr) | 2018-10-11 | 2019-10-11 | Modulateurs de promédicaments de la voie de réponse intégrée au stress |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53861A MA53861A (fr) | 2021-08-18 |
MA53861B1 true MA53861B1 (fr) | 2023-01-31 |
Family
ID=68387427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53861A MA53861B1 (fr) | 2018-10-11 | 2019-10-11 | Modulateurs de promédicaments de la voie de réponse intégrée au stress |
Country Status (34)
Country | Link |
---|---|
US (2) | US11149043B2 (fr) |
EP (2) | EP3864003B1 (fr) |
JP (2) | JP7203964B2 (fr) |
KR (2) | KR20220151232A (fr) |
CN (2) | CN116283647A (fr) |
AR (2) | AR116693A1 (fr) |
AU (2) | AU2019356565B2 (fr) |
BR (2) | BR122023020960A2 (fr) |
CA (1) | CA3115668A1 (fr) |
CL (1) | CL2021000875A1 (fr) |
CO (1) | CO2021006098A2 (fr) |
CR (1) | CR20230182A (fr) |
DK (1) | DK3864003T3 (fr) |
DO (1) | DOP2021000064A (fr) |
EC (1) | ECSP21032861A (fr) |
ES (1) | ES2938061T3 (fr) |
FI (1) | FI3864003T3 (fr) |
HR (1) | HRP20230222T1 (fr) |
HU (1) | HUE061297T2 (fr) |
IL (2) | IL300799A (fr) |
LT (1) | LT3864003T (fr) |
MA (1) | MA53861B1 (fr) |
MD (1) | MD3864003T2 (fr) |
MX (1) | MX2021004163A (fr) |
PE (1) | PE20211277A1 (fr) |
PH (1) | PH12021550786A1 (fr) |
PL (1) | PL3864003T3 (fr) |
PT (1) | PT3864003T (fr) |
RS (1) | RS64013B1 (fr) |
SG (1) | SG11202103531YA (fr) |
SI (1) | SI3864003T1 (fr) |
TW (2) | TWI832295B (fr) |
UY (1) | UY38415A (fr) |
WO (1) | WO2020077217A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
MX2020004557A (es) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
BR112020011914A2 (pt) | 2017-12-13 | 2020-11-24 | Praxis Biotech LLC | inibidores de via de resposta de tensão integrada |
BR112020023115A2 (pt) | 2018-06-05 | 2021-02-02 | Praxis Biotech LLC | inibidores da via integrada de resposta a tensão |
TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
IL296220A (en) | 2020-03-11 | 2022-11-01 | Evotec Int Gmbh | Modulators for an integrated stress response pathway |
JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
WO2022084448A1 (fr) | 2020-10-22 | 2022-04-28 | Evotec International Gmbh | Modulateurs de la voie de réponse intégrée au stress |
KR20230110510A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
US11845736B2 (en) | 2021-10-01 | 2023-12-19 | Empathbio, Inc. | Prodrugs of MDMA, MDA, and derivatives thereof |
US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212A (en) | 1847-07-31 | Richard m | ||
US162A (en) | 1837-04-17 | Island | ||
GB1026506A (en) | 1962-10-17 | 1966-04-20 | Du Pont | Bicyclodiamines and preparation thereof |
US3264351A (en) | 1964-07-08 | 1966-08-02 | American Home Prod | 1, 4-diaminobicyclo [2.2.2] octanes |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JPH02215779A (ja) | 1989-02-14 | 1990-08-28 | Kuraray Co Ltd | カルボン酸アミド誘導体類及びその医薬用途 |
US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
AU675730B2 (en) | 1993-07-16 | 1997-02-13 | Merck & Co., Inc. | Substituted piperazinylcamphor derivatives as oxytocin antagonists |
AR038377A1 (es) | 2002-02-08 | 2005-01-12 | Merck & Co Inc | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) |
CA2473778A1 (fr) | 2002-02-08 | 2003-08-14 | Merck & Co., Inc. | Derives de n-biphenylmethyl aminocycloalcanecarboxamide |
US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
EP1706384A1 (fr) | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Agents therapeutiques i |
KR20060129021A (ko) | 2004-02-18 | 2006-12-14 | 교린 세이야꾸 가부시키 가이샤 | 비시클로아미드 유도체 |
CN102816081A (zh) | 2005-01-05 | 2012-12-12 | 雅培制药有限公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
NZ566068A (en) | 2005-08-08 | 2011-03-31 | Argenta Discovery Ltd | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
WO2008075196A1 (fr) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Dérivés du benzamidazole |
CA2735420C (fr) | 2008-09-08 | 2016-06-28 | Merck Patent Gmbh | Pyrimidines macrocycliques en tant qu'inhibiteurs de proteine kinase |
HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
WO2011087758A1 (fr) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Dérivés amide de l'adamantyle et utilisations associées |
TWI538905B (zh) | 2010-12-22 | 2016-06-21 | H 朗德貝克公司 | 雙環[3.2.1]辛基醯胺衍生物及其用途 |
WO2013161980A1 (fr) | 2012-04-27 | 2013-10-31 | 東レ株式会社 | Dérivé de cyclohexanediamide et son utilisation à des fins médicales |
JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | eIF2α経路の調節因子 |
US9580459B2 (en) * | 2013-04-26 | 2017-02-28 | Metselex, Inc. | Water-soluble ursodeoxycholic acid prodrugs |
US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
SG11201608242XA (en) | 2014-04-04 | 2016-10-28 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US20150362847A1 (en) | 2014-06-13 | 2015-12-17 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus |
US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US20180148418A1 (en) | 2015-05-05 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
WO2017040606A1 (fr) | 2015-08-31 | 2017-03-09 | Proteostasis Therapeutics, Inc. | Dérivés d'isoxazole destinés à être utilisés dans le traitement de maladies et de troubles pulmonaires |
TW201722958A (zh) | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
TW202304851A (zh) * | 2016-05-05 | 2023-02-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
ES2913929T3 (es) | 2016-06-08 | 2022-06-06 | Glaxosmithkline Ip Dev Ltd | Compuestos químicos como inhibidores de la ruta de ATF4 |
US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
CN106349130B (zh) | 2016-08-25 | 2018-01-23 | 潍坊大有生物化工有限公司 | 一种新的氟苯尼考的合成方法 |
WO2018225093A1 (fr) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques utilisés comme inhibiteurs de la voie atf4 |
MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
SI3676297T1 (sl) | 2017-09-01 | 2023-12-29 | Denali Therapeutics Inc. | Spojine, sestavki in postopki |
CN112204012B (zh) | 2017-11-02 | 2023-12-26 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
CN112218869A (zh) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
JP7184889B2 (ja) | 2017-11-02 | 2022-12-06 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
EP3704091A1 (fr) | 2017-11-02 | 2020-09-09 | Calico Life Sciences LLC | Modulateurs de la voie de réponse intégrée au stress |
CN112204006B (zh) | 2017-11-02 | 2023-11-28 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
MX2020004557A (es) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
EP3768660A1 (fr) | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulateurs du facteur 2 d'initiation eucaryote |
CN108517001A (zh) * | 2018-05-17 | 2018-09-11 | 江苏恩华络康药物研发有限公司 | 水溶性别孕烯醇酮衍生物及其用途 |
EP3820843A1 (fr) | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Composés chimiques |
TWI832295B (zh) * | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
KR20220016468A (ko) | 2019-04-30 | 2022-02-09 | 칼리코 라이프 사이언시스 엘엘씨 | 통합 스트레스 경로의 조절인자로서의 치환된 사이클로알킬 |
AU2020266592A1 (en) | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cyclolakyls as modulators of the integrated stress pathway |
-
2019
- 2019-10-09 TW TW111122712A patent/TWI832295B/zh active
- 2019-10-09 TW TW108136745A patent/TWI771621B/zh active
- 2019-10-11 AR ARP190102911A patent/AR116693A1/es unknown
- 2019-10-11 BR BR122023020960-5A patent/BR122023020960A2/pt unknown
- 2019-10-11 LT LTEPPCT/US2019/055850T patent/LT3864003T/lt unknown
- 2019-10-11 MX MX2021004163A patent/MX2021004163A/es unknown
- 2019-10-11 AU AU2019356565A patent/AU2019356565B2/en active Active
- 2019-10-11 EP EP19795413.4A patent/EP3864003B1/fr active Active
- 2019-10-11 EP EP22210424.2A patent/EP4209483A1/fr active Pending
- 2019-10-11 SI SI201930432T patent/SI3864003T1/sl unknown
- 2019-10-11 MD MDE20210768T patent/MD3864003T2/ro unknown
- 2019-10-11 CR CR20230182A patent/CR20230182A/es unknown
- 2019-10-11 KR KR1020227038367A patent/KR20220151232A/ko not_active Application Discontinuation
- 2019-10-11 HR HRP20230222TT patent/HRP20230222T1/hr unknown
- 2019-10-11 PL PL19795413.4T patent/PL3864003T3/pl unknown
- 2019-10-11 JP JP2021519747A patent/JP7203964B2/ja active Active
- 2019-10-11 CA CA3115668A patent/CA3115668A1/fr active Pending
- 2019-10-11 UY UY0001038415A patent/UY38415A/es unknown
- 2019-10-11 ES ES19795413T patent/ES2938061T3/es active Active
- 2019-10-11 CN CN202211415030.XA patent/CN116283647A/zh active Pending
- 2019-10-11 PT PT197954134T patent/PT3864003T/pt unknown
- 2019-10-11 RS RS20230160A patent/RS64013B1/sr unknown
- 2019-10-11 KR KR1020217013975A patent/KR102464077B1/ko active IP Right Grant
- 2019-10-11 DK DK19795413.4T patent/DK3864003T3/da active
- 2019-10-11 SG SG11202103531YA patent/SG11202103531YA/en unknown
- 2019-10-11 IL IL300799A patent/IL300799A/en unknown
- 2019-10-11 FI FIEP19795413.4T patent/FI3864003T3/fi active
- 2019-10-11 CN CN201980080430.XA patent/CN113423685B/zh active Active
- 2019-10-11 HU HUE19795413A patent/HUE061297T2/hu unknown
- 2019-10-11 BR BR112021006789-2A patent/BR112021006789A2/pt active Search and Examination
- 2019-10-11 MA MA53861A patent/MA53861B1/fr unknown
- 2019-10-11 WO PCT/US2019/055850 patent/WO2020077217A1/fr active Application Filing
- 2019-10-11 PE PE2021000488A patent/PE20211277A1/es unknown
-
2021
- 2021-04-07 IL IL282153A patent/IL282153B2/en unknown
- 2021-04-08 PH PH12021550786A patent/PH12021550786A1/en unknown
- 2021-04-09 CL CL2021000875A patent/CL2021000875A1/es unknown
- 2021-04-09 DO DO2021000064A patent/DOP2021000064A/es unknown
- 2021-04-09 US US17/227,071 patent/US11149043B2/en active Active
- 2021-05-10 EC ECSENADI202132861A patent/ECSP21032861A/es unknown
- 2021-05-11 CO CONC2021/0006098A patent/CO2021006098A2/es unknown
- 2021-09-02 US US17/446,807 patent/US20220251123A1/en active Pending
-
2022
- 2022-04-07 AR ARP220100871A patent/AR125309A2/es unknown
- 2022-12-27 JP JP2022209518A patent/JP2023040106A/ja active Pending
-
2024
- 2024-01-02 AU AU2024200013A patent/AU2024200013A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53861B1 (fr) | Modulateurs de promédicaments de la voie de réponse intégrée au stress | |
MA44861B1 (fr) | Modulateurs de la voie de réponse intégrée au stress | |
MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
PH12020550523A1 (en) | Modulators of the integrated stress pathway | |
WO2019090085A8 (fr) | Modulateurs de la voie de réponse intégrée au stress | |
PH12020550524A1 (en) | Modulators of the integrated stress pathway | |
MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
AU2017261336A1 (en) | Modulators of the integrated stress pathway | |
MX2020004557A (es) | Moduladores de la vía de estrés integrada. | |
MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
AU2017260374A1 (en) | Modulators of the integrated stress pathway | |
MA54231B1 (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
MX2020004537A (es) | Moduladores de la vía integrada del estrés. | |
MA47392B1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
ECSP23040124A (es) | Moduladores de la vía integrada del estrés | |
EA202091111A1 (ru) | Модуляторы интегрированного стресса | |
EA202091110A1 (ru) | Модуляторы интегрированного стресса | |
EA202091109A1 (ru) | Модуляторы интегрированного стресса | |
CL2023000234A1 (es) | Moduladores de la vía de estrés integrada |